Skip to main content
Premium Trial:

Request an Annual Quote

Bionomics Licenses North American, Japanese Market Rights to Gene-Based Epilepsy Test

NEW YORK, Sept. 27 (GenomeWeb News) - Bionomics said yesterday that it has signed a deal giving the North American and Japanese market rights to its gene-based severe myoclonic epilepsy of infancy diagnostic test to Athena Diagnostics.


Under the agreement, Athena will pay Bionomics upfront fees, sales milestones, and royalties. Additional terms were not disclosed.


According to Bionomics, Athena plans to make the product available later this year to the more than 5,000 neurologists for whom it performs diagnostic tests. The company added that it estimates about 240,000 children in the US may be candidates for testing.


The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.